Identification of isoliquiritigenin as a promising compound targeting lactate metabolism for heart failure alleviation
7.5
来源：
Nature
关键字：
mRNA
发布时间：
2025-10-10 03:43
摘要：
Isoliquiritigenin, a compound identified for its ability to target lactate metabolism, shows promise in alleviating heart failure (HF) by stabilizing the PYGL protein, which enhances lactate production in cardiomyocytes. In murine models, isoliquiritigenin administration significantly improved cardiac function and reduced HF pathology. The study highlights the potential of isoliquiritigenin as a novel therapeutic agent for HF, warranting further preclinical and clinical investigations.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+重点关注领域符合度
business_impact
0.5分+商业影响力
scientific_rigor
1.5分+数据支撑的科学性
timeliness_innovation
1.5分+时效性与创新性
investment_perspective
2.5分+BOCG投资视角
market_value_relevance
1.0分+市场价值相关性
team_institution_background
0.5分+团队与机构背景
technical_barrier_competition
0.5分+技术壁垒与竞争格局
关键证据
Isoliquiritigenin demonstrates therapeutic potential in alleviating HF by targeting lactate metabolism.
Molecular docking simulations predicted a strong and stable interaction between isoliquiritigenin and PYGL protein.
In vivo experiments validated the therapeutic potential of isoliquiritigenin for HF treatment.
真实性检查
否
AI评分总结
Isoliquiritigenin, a compound identified for its ability to target lactate metabolism, shows promise in alleviating heart failure (HF) by stabilizing the PYGL protein, which enhances lactate production in cardiomyocytes. In murine models, isoliquiritigenin administration significantly improved cardiac function and reduced HF pathology. The study highlights the potential of isoliquiritigenin as a novel therapeutic agent for HF, warranting further preclinical and clinical investigations.